尽管当前A股市场出现了波动，医药板块也面临了一些调整，但总体市场人气仍然活跃。 另一方面，郑宁并不追求短期的业绩排名，而是更希望一轮牛熊周期下来，每一个位置买入的持有人都 能赚到钱。他不断强调要"知足"，即不要总是去追求高赔率的机会，而是不断衡量组合的风险收益比， 通过风险定价力争为持有人提升产品的获得感。 这一投资理念也体现在了他管理的产品中。他所掌管的产品收益表现不俗，在同类产品中排名较为靠 前。据银河证券数据显示，中银创新医疗A过去一年收益率排名同类前五（4/85）、过去三年和过去五 年排名均位于同类前三（2/66和3/37），另外，中银医疗保健A过去三年收益率排名也位居同类前三 （3/66），中银港股通医药A过去一年收益率在同类中排名第一（1/42）。（中银创新医疗、中银医疗 保健同类排名均为混合基金-行业偏股型基金-医药医疗健康行业偏股型基金(A类)；中银港股通医药同 类排名为混合基金-港股通偏股型基金-港股通偏股型基金(A类)；排名来源于银河证券，截至 2025.8.31） 作为市场上较早一批重仓创新药的医药基金经理，郑宁刚开始管理医药基金就恰好遇到了板块的阶段性 高点，随后遇到了板块漫长的调整。 ...

Core Viewpoint - The pharmaceutical sector in the A-share market has shown structural performance, with the innovative drug index rising by 60.77% year-to-date, significantly outperforming the overall A-share index by 22.14% [1] Group 1: Pharmaceutical Sector Performance - The pharmaceutical sector has been active this year, with innovative drug indices leading the gains [1] - The performance of pharmaceutical-themed mutual funds has attracted investor attention, with notable returns reported [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked well among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1] Group 2: Fund Manager Insights - Fund manager Zheng Ning employs a long-term pricing focus, filtering out market noise to concentrate on long-term implied returns [3] - The performance of Zhongyin Hong Kong Stock Connect Pharmaceutical A has shown significant growth, with a net value growth rate of 70.08% in the first half of 2025 [3] - Zheng Ning has managed multiple funds, consistently achieving competitive returns compared to benchmarks [4][6] Group 3: Market Drivers - The recent rise in the innovative drug sector is driven by fundamental improvements, including advancements in R&D, successful profit realization, and favorable policies [2] - The innovative drug industry is expected to have substantial growth potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2]

Core Insights - Domestic innovative drugs are experiencing a surge in overseas collaborations, with over 50 global partnership agreements reached by mid-2025, totaling more than $48.4 billion [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has seen a year-to-date increase of 93.18% as of July 18, 2025, indicating strong investor interest in the sector [1] - Supportive measures for innovative drug development have been implemented, enhancing market accessibility and encouraging increased R&D investment from pharmaceutical companies [1] - The integration of AI technology in drug development is significantly reducing R&D cycles and costs, accelerating the internationalization of innovative drugs [1] Industry Performance - The innovative drug sector is becoming a key focus in the market, with notable performance from certain healthcare funds, such as Zhongyin Innovation Medical A and Zhongyin Hong Kong Stock Connect Medical A, which have increased by 63.64% and 84.18% respectively over the past year [2] - The total profit for the innovative drug sector is projected to grow from 60 billion yuan to 600-900 billion yuan over the next 10-15 years, highlighting its potential for future growth [2] Fund Performance - Zhongyin Hong Kong Stock Connect Medical A has shown a net value growth rate of 70.08% in the first half of 2025, outperforming its benchmark by 32.79% [3] - Zhongyin Innovation Medical A has achieved a net value growth rate of 54.08% in the first half of 2025, significantly exceeding its benchmark [4] - The performance of other funds managed by Zhongyin, such as Zhongyin Healthcare Mixed A and C, also reflects strong growth, with 51.59% and 51.31% increases respectively in the first half of 2025 [5]

Core Insights - The article discusses the performance of various funds in the first quarter of 2025, highlighting significant profits and losses among them [1][2][3] Fund Performance Summary - E Fund Blue Chip Selection Mixed Fund (005827.OF) achieved the highest quarterly profit of 3.172 billion, making it the only equity fund to surpass the 3 billion mark [1][2] - The second tier of profitable funds includes Wanji Industry Selection (18.81 million), China Merchants Advantage Enterprises A (16.05 million), and others, indicating a clear performance hierarchy [1][2] - The article notes that the medical sector showed a strong recovery, with China Europe Medical Innovation A reversing a previous loss of 1.718 billion to achieve a quarterly return of 20.33% [2][6] Losses and Challenges - The top loss was recorded by Xingquan Trend Investment (163402.OF) with a quarterly loss of 935 million, reflecting a year-to-date return of -9.64% [3][4] - Other notable losses include Caizhong Value Momentum A (-648 million) and Caizhong Growth Selection A (-521 million), both managed by the same individual, indicating significant challenges in the TMT sector [6][7] - The article emphasizes the risks associated with large funds that may struggle to convert scale into effective returns, as seen with E Fund Blue Chip Selection [6][7] Market Dynamics - The article highlights the contrasting performance of funds, suggesting that investors should be cautious of both oversized funds that may underperform and smaller funds that may show high returns without substantial profit realization [7][8] - The ongoing market differentiation in the second quarter is expected to continue influencing fund performance, with a focus on those that can maintain scale flexibility while efficiently converting profits [7][8]